Opigolix - Astellas Pharma
Alternative Names: ASP-1707Latest Information Update: 05 Nov 2023
At a glance
- Originator Astellas Pharma
- Class Antineoplastics; Antirheumatics; Benzimidazoles; Small molecules
- Mechanism of Action LHRH receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Endometriosis; Prostate cancer; Rheumatoid arthritis
Most Recent Events
- 30 Apr 2018 Discontinued - Phase-I for Rheumatoid arthritis (Combination therapy) in Moldova (PO) (Astellas Pharma pipeline, May 2018)
- 30 Apr 2018 Discontinued - Phase-II for Endometriosis in United Kingdom, Romania, Poland, Hungary, Germany, Bulgaria, Belgium, France, France, Ukraine, Japan (PO) (Astellas Pharma pipeline, May 2018)
- 30 Apr 2018 Discontinued - Phase-II for Rheumatoid arthritis in Japan (PO) (Astellas Pharma pipeline, May 2018)